None
Quote | Epigenomics Ag S/Adr (OTCMKTS:EPGNY)
Last: | $2.39 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.39 |
High: | $0 |
Low: | $0 |
Volume: | 112 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Epigenomics Ag S/Adr (OTCMKTS:EPGNY)
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Summary As EXAS continues shifting its business models from "growth at all costs" to "profitable growth" in response to rising capital costs, its sales will expand at a slower pace. Despite the expected normalization in growth, in my view, the market will likely reward improved ma...
Message Board Posts | Epigenomics Ag S/Adr (OTCMKTS:EPGNY)
Subject | By | Source | When |
---|---|---|---|
EPGNY: effective Dec. 30,2022 a one for 4 | Renee | investorshub | 12/29/2022 1:51:05 PM |
znewcar1: PGNY 27% v5,1M c26.13 f84,8M H27.49 gap up hit 24.4 dip to S@24.5 near the open then climb | znewcar1 | investorshangout | 05/13/2020 8:39:22 PM |
PoemStone: DGAP-News: Epigenomics AG / Key word(s): Miscellaneous Correction of the Corporate News | PoemStone | investorshangout | 03/18/2019 4:46:20 PM |
BLOCKBUSTER - otherwise no words ... | Steve1HD1 | investorshub | 04/15/2016 12:36:19 PM |
"We are excited by the FDA's decision to | Steve1HD1 | investorshub | 04/14/2016 7:26:31 AM |
News, Short Squeeze, Breakout and More Instantly...
Epigenomics Ag S/Adr Company Name:
EPGNY Stock Symbol:
OTCMKTS Market:
Under the primary base case analysis, annual m SEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard ® every three years, albeit at a higher colonoscopy referral rate ...
Dover, Delaware--(Newsfile Corp. - June 17, 2020) - Encode Ideas, L.P. Initiates Research on Epigenomics AG (Xetra: ECX.DE) (FSE: ECX) (OTC: EPGNF). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a h...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...